BriefingHome / GU / Bladder / urothelialSunRISe-3: TAR-200 plus cetrelimab or TAR-200 versus BCG in BCG-naive high-risk NMIBC (trial in progress).e.g. ESMO 2023 2407TiP. No published utDNA results found.Urine tumor DNA